



**FOR IMMEDIATE RELEASE**

## **Independent Data Safety Monitoring Board recommends continuation of Phase 3 trial with TH9507**

**Montréal, July 6<sup>th</sup>, 2006** - Theratechnologies (TSX: TH) announced today that an independent Data and Safety Monitoring Board (DSMB) has recommended that its Phase 3 clinical study on TH9507 for the treatment of HIV associated lipodystrophy be continued as currently being conducted. The DSMB is comprised of independent medical experts and is responsible for monitoring the safety aspects of the Phase 3 clinical study.

“The DSMB’s favourable recommendation reinforces our confidence in the safety profile of TH9507. This profile will be an important asset in our commercialisation strategy,” said Yves Rosconi, President and Chief Executive Officer of Theratechnologies. “With 280 patients having now completed 13 weeks of treatment, the trial continues to progress on schedule and we expect the first Phase 3 study results around the end of this year,” he concluded.

The recommendation made by the DSMB is based on a recent review of the safety data on 181 patients who have been treated for 3 months. After reviewing the safety data, the DSMB concluded that the trial should continue as per protocol.

### **About Theratechnologies**

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company that discovers or acquires novel therapeutic products for development and commercialization. These products target unmet medical needs in commercially attractive specialty markets. The most advanced program is in Phase 3 clinical development in HIV-associated lipodystrophy. The Company also has other promising projects at various stages of development.

### **Forward-looking statements**

*This press release contains a forward-looking statement regarding the date of the results of the first TH9507 Phase 3 clinical study. By its very nature, this statement involve uncertainties and inherent risks, both general and specific, which give rise to the possibility that this prediction will not materialize. We therefore caution investors against placing undue reliance on this statement. We refer you to pages 16 and 17 of the 2005 annual report, which contain a more exhaustive analysis of the risks and uncertainties connected to the business of the Company. We have no obligation to update the forward-looking statement and we do not undertake to do so.*

###

### **Contact:**

Tobie Trudel  
Director, Investor Relations and Communications  
Phone: (514) 336-4804, ext. 229  
Email: [ttrudel@theratech.com](mailto:ttrudel@theratech.com)

Theratechnologies Inc.

2310 Alfred-Nobel Blvd., Montréal, Québec, Canada H4S 2A4

Phone: (514) 336-7800 • Fax: (514) 336-7242 • [www.theratech.com](http://www.theratech.com) • [thera@theratech.com](mailto:thera@theratech.com)

Luc Tanguay  
Senior Executive Vice-President  
and Chief Financial Officer  
Phone: (514) 336-4804, ext. 204  
Email: [ltanguay@theratech.com](mailto:ltanguay@theratech.com)